Department of Radiation Oncology, St, Vincent's Hospital, College of Medicine, The Catholic University of Korea, 93-6 Ji-dong Paldal-gu, Suwon, Kyeonggi-do, Republic of Korea.
Radiat Oncol. 2013 Jul 16;8:181. doi: 10.1186/1748-717X-8-181.
Tomotherapy for intensity-modulated radiation has been demonstrated to reduce unnecessary irradiations to adjacent organs at risk (OARs). The purpose of this study was to compare the dosimetric parameters between Tomotherapy and three-dimensional conformal radiotherapy (3D-CRT) in rectal cancer patients.
We redesigned three-dimensional conformal plans for 20 rectal cancer patients who had received short-course preoperative radiotherapy with Tomotherapy. The target coverage for 3D-CRT and Tomotherapy was evaluated with the following including the mean dose, V(nGy), D(min), D(max), radiation conformality index (RCI), and radical dose homogeneity index (rDHI).
The mean PTV dose for Tomotherapy is significantly higher than that observed for the 3D-CRT (p = 0.043). However, there is no significant difference in the V(23.25Gy), V(26.25Gy), V(27.5Gy), and RCI values between Tomotherapy and 3D-CRT. However, the average rDHI (p < 0.001) value for Tomotherapy was significantly lower than that reported for the 3D-CRT. Tomotherapy significantly lowered the mean level of irradiation doses to the bladder, small bowel, and femur heads as compared to 3D-CRT.
Tomotherapy could produce a favorable target coverage and significant dose reduction for the OARs at the expense of acceptable dose inhomogeneity of the PTV compared with 3D-CRT in rectal cancer patients.
调强适形放疗(Tomotherapy)已被证实可减少相邻危及器官(OARs)的不必要照射。本研究旨在比较直肠癌患者接受 Tomotherapy 和三维适形放疗(3D-CRT)的剂量学参数。
我们重新设计了 20 例接受短程术前放疗的直肠癌患者的三维适形计划。使用以下指标评估 3D-CRT 和 Tomotherapy 的靶区覆盖情况,包括平均剂量、V(nGy)、D(min)、D(max)、适形指数(RCI)和剂量均匀性指数(rDHI)。
Tomotherapy 的 PTV 平均剂量显著高于 3D-CRT(p=0.043)。然而,Tomotherapy 和 3D-CRT 的 V(23.25Gy)、V(26.25Gy)、V(27.5Gy)和 RCI 值没有显著差异。然而,Tomotherapy 的平均 rDHI 值显著低于 3D-CRT(p<0.001)。与 3D-CRT 相比,Tomotherapy 显著降低了膀胱、小肠和股骨头的平均照射剂量。
与 3D-CRT 相比,Tomotherapy 可在直肠癌患者中提供更好的靶区覆盖和显著降低 OAR 剂量,但 PTV 的剂量不均匀性可接受。